<div id="readability-page-1"><div>By Colin Kellaher A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer. The companies on Wednesday said Merck's Keytruda coupled with Padcev from Pfizer and Astellas showed significantly improved survival for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy. The study met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival, as well as in overall survival, a key secondary endpoint, the companies said. Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, said they plan to discuss the study results with global health authorities for potential regulatory filings. Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Padcev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late 2023. The combination is already approved for the treatment of adults with locally advanced or metastatic urothelial cancer in the U.S., the European Union, Japan and several other countries around the world. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires12-17-25 0753ET</div></div>

安斯泰莱制药(ADR)

辉瑞

默克

默克、辉瑞和安斯泰莱制药的药物组合 Keytruda 和 Padcev 在第二阶段 III 研究中成功治疗肌肉侵袭性膀胱癌。研究显示生存率显著改善，达到了主要和次要终点。这些公司计划与卫生当局讨论结果，以进行监管申请。该组合已在全球范围内获得对晚期尿路上皮癌治疗的批准

Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study

- 默克、辉瑞和阿斯利康的联合癌症药物在晚期膀胱癌研究中成功。  
- 研究显示此组合显著改善肌肉侵袭性膀胱癌患者的生存率。  
- 公司计划与全球卫生机构讨论研究结果以拟定监管申请。

默克、辉瑞和安斯泰莱制药的药物组合在第二个三期膀胱癌研究中取得成功